Key points are not available for this paper at this time.
By studying drugs that have been withdrawn from the market for safety reasons, we can gain valuable insight into postmarketing surveillance as well as the process for approving new drugs. In the past decade there has been a major shift in the funding structure of the Therapeutic Products Directorate
Joel Lexchin (Tue,) studied this question.